Note: Ingredients listed on restricted chemical lists
EC/CAS
232-674-9/9004-34-6
Name of the chemical
cellulose
Concentration
55-60%
General Information
Version
2.1.0
Revision date
2019-05-01
Product name
IDHIFATM
Product Synonyms
For enasidenib: 2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-[2- (trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2- yl)amino]propan-2-ol
Chemical name
Mixture - contains a substituted triazine
1.2.1 Relevant identified uses
Bulk formulated pharmaceutical mixture/ Formulated pharmaceutical product/ of the substance or mixture packaged in final form for patient use mixture and uses
Emergency telephone
+1 (800) 424-9300, +1 (703) 527-3887
Icons in SDS
Company Information
company name
Celgene Corporation
e-mail address of the competent person responsible for the Safety Data Sheet
MSDScoordinator@Celgene.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H361f, H372
Hazard statements
Code
Statements
H361f
Suspected of damaging fertility
Section 2
SECTION 2: Hazards identification
WHMIS 2015 Classification of the substance or mixture Drugs in the finished state and intended for the final user are not subject to labeling in the US, EU or Canada. Consult prescribing/packaging information The classification and labeling listed below is for bulk drug product HAZARDS IDENTIFICATION …continued Globally Harmonized System [GHS] Specific Target Organ Toxicity (repeated exposure) - Category 1. Reproductive Toxicity - Category 2
Signal word
Danger
Hazard statements
H372 - Causes damage to the immune system through prolonged or repeated exposure. H361f - Suspected of damaging fertility. Wash hands thoroughly after handling. P270 - Do not eat, drink or smoke when using this product. P280 - Wear eye/face protection. P308 + P313 - IF exposed or concerned: get medical advice/attention. P314 - Get medical advice/attention if you feel unwell. P405 - Store locked up. P501 - Dispose of contents/container to location in accordance with local/regional/national/international regulations.
Precautionary statements
P260 - Do not breathe dust. P264 - Wash hands thoroughly after handling. P264 -
2.3 Other hazards
Enasidenib is an orally available anticancer drug. The most commonly reported adverse effects in cancer patients were elevated bilirubin, gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea), and decreased appetite. Less frequently albeit more severe adverse effects included leukocytosis (increased white blood cell counts) and differentiation syndrome, including fever, acute kidney failure, dyspnea (shortness of breath), acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. Note This mixture is classified as hazardous under GHS as implemented by Regulation
2.1 Classification of the substance or mixture
Drugs in the finished state and intended for the final user are not subject to substance or mixture
